Get the Stockscreener App
29.96
2.98%
-0.92
After Hours:
29.96
Roivant Sciences Ltd stock is traded at $29.96, with a volume of 5.87M.
It is down -2.98% in the last 24 hours and up +2.78% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$30.88
Open:
$30.75
24h Volume:
5.87M
Relative Volume:
1.03
Market Cap:
$21.55B
Revenue:
$13.31M
Net Income/Loss:
$-1.01B
P/E Ratio:
-25.64
EPS:
-1.1685
Net Cash Flow:
$-766.86M
1W Performance:
+2.29%
1M Performance:
+2.78%
6M Performance:
+48.17%
1Y Performance:
+173.86%
1-Day Range:
$29.88
$30.86
1-Week Range:
$27.85
$32.79
52-Week Range:
$10.59
$32.79
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
29.96 | 22.21B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Outperform |
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant gains after mid-stage trial data for Immunovant’s main asset - MSN
Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors? - Sahm
[Form 4] Roivant Sciences Ltd. Insider Trading Activity - Stock Titan
Roivant shares climb on earnings beat despite revenue shortfall (ROIV) - MSN
Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts - MSN
ROIV Stock Price Prediction 2025-2026 | Roivant Sciences Ltd Forecast - 24/7 Wall St.
H.C. Wainwright reiterates Roivant Sciences stock rating on IMVT-1402 data By Investing.com - Investing.com South Africa
ROIV Maintained by Citigroup -- Price Target Raised to $42.00 - GuruFocus
Roivant Sciences Is Maintained at Buy by Citigroup - Moomoo
ROIV Reiterates by HC Wainwright & Co. -- Price Target Maintained at $34 - GuruFocus
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha
Piper Sandler reiterates Roivant Sciences stock rating on trial progress By Investing.com - Investing.com Australia
Leerink raises Roivant Sciences stock price target on drug data By Investing.com - Investing.com South Africa
TD Cowen raises Roivant Sciences stock price target to $41 on trial data - Investing.com Australia
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $34 to $42 - Moomoo
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences Ltd. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ROIV) 2026-05-21 - Seeking Alpha
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Roivant (ROIV) Climbs 15% on Swing to Profits - Insider Monkey
Earnings call transcript: Roivant Sciences surprises with Q4 2026 EPS beat By Investing.com - Investing.com South Africa
Roivant Sciences Earnings Call Highlights High-Impact Pipeline - TipRanks
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Long Term Bullish Narratives - simplywall.st
Earnings Call Summary | Roivant Sciences(ROIV.US) Q4 2025 Earnings Conference - 富途牛牛
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.68, Implies 30% Upside - TradingView
Roivant/Immunovant Find Success In Tough-To-Treat RA, Where J&J Failed - Citeline News & Insights
Roivant Sciences (ROIV) Surges 15.2% on Strong Market Performanc - GuruFocus
Roivant Sciences stock hits all-time high of 30.35 USD By Investing.com - Investing.com Australia
Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ... By GuruFocus - Investing.com Canada
Roivant Sciences (ROIV) Surges 14.8% to $32.38 - AlphaStreet
Roivant Sciences earnings beat by $0.57, revenue fell short of estimates - Investing.com India
Roivant reports Q4 FY2026 income on Moderna legal settlement - grafa.com
Why is Roivant Sciences stock surging today? By Investing.com - Investing.com South Africa
ROIV: High efficacy in refractory RA, strong cash, and major launches expected in the coming year - TradingView
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug -- Barrons.com - Moomoo
Roivant Sciences Shares Jump 14.43% to $32.28 on Strong IMVT-1402 Rheumatoid Arthritis Data - International Business Times Australia
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 - marketscreener.com
Earnings call transcript: Roivant Sciences Q4 2026 reveals strategic growth By Investing.com - Investing.com Australia
Sector Update: Healthcare - Moomoo
Roivant Sciences Q4 Earnings Call Highlights - Barchart.com
Immunovant Q4 Earnings Call Highlights - Yahoo Finance
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Movin - Benzinga
Roivant Sciences Ltd.Common Shares (NQ: ROIV - The Chronicle-Journal
Roivant Sciences stock hits all-time high of 30.35 USD - Investing.com
Roivant Sciences Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Roivant Sciences Swings to Fiscal Q4 Net Income, Revenue Decreases - Moomoo
Earnings call transcript: Roivant Sciences surprises with Q4 2026 EPS beat - Investing.com Canada
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript - Benzinga
Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV) - Yahoo Finance
Roivant shares jump 10% on earnings beat despite revenue miss By Investing.com - Investing.com Nigeria
Roivant Sciences : Financial Results and Business Updates for the Year Ended March 31 2026 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):